MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/112.5/0.1/20.12.24

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/112.5/0.1/20.12.24 Share Price

DE000MB3P3F0

Real-time Bid/Ask 07:50:45 02/07/2024 pm IST
0.044 ^EUR / 0.047 ^EUR	+4.55%

Current month	-6.38%
1 month	+91.30%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/112.5/0.1/20.12.24

Latest news about GILEAD SCIENCES, INC.

HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	02/07	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	02/07	CI
Gilead Benefit Helps Employees Navigate Cancer Care	01/07	AQ
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	27/06	CI

More news

Quotes 5-day view

Date	Price	Change
02/24/02	0.043	-2.27%
01/24/01	0.044	-6.38%
28/24/28	0.047	+6.82%
27/24/27	0.044	0.00%
26/24/26	0.044	-2.22%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 05:42 pm IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Morgan Stanley
WKN	MB3P3F
ISIN	DE000MB3P3F0
Date issued	15/02/2023
Strike	112.5 $
Maturity	20/12/2024 (171 Days)
Parity	10 : 1
Emission price	0.49 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	0.55 €
Lowest since issue	0.015 €
Spread	0.003 €
Spread %	6.38%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

68.64 USD

Average target price

82.97 USD

Spread / Average Target

+20.87%

Consensus